Physiology & Behavior
October 1, 2024
Jasmine Shakir, Megan Pedicini, Brianna C Bullock et al.
5 citations
There is growing interest in the therapeutic potential of psilocybin for the treatment of a wide variety of medical problems, and even for the promotion of wellbeing among healthy individuals. Interestingly, among the many proposed indications, both obesity and anorexia nervosa (AN) have been discussed. However, the effect of psilocybin on appetitive behavior and metabolism is not well known....
Psychiatry and Clinical Neurosciences
October 1, 2024
Shakila Meshkat, Fatemeh Gholaminezhad, Eric Vermetten et al.
24 citations
Psilocybin is a classic psychedelic with demonstrated preliminary clinical efficacy in a range of psychiatric disorders. Evaluating the impact of psilocybin on cognitive function is essential to unravel its potential benefits and risks. In this systematic review, we assessed psilocybin's effect on cognitive function through a comprehensive search of electronic databases from inception to...
Palliative & Supportive Care
October 1, 2024
Marianne Masse-Grenier, Sue-Ling Chang, Ariane Bélanger et al.
4 citations
Promising studies show that psilocybin-assisted therapy relieves existential distress in patients with serious illnesses, a difficult condition to treat with current treatment options. There is growing interest in this therapy in palliative care. Canada recently amended its laws to allow physicians to request psilocybin for end-of-life distress. However, barriers to access remain. Since...
bioRxiv (Cold Spring Harbor Laboratory)
September 30, 2024
Conor P. Lane, Veronica Tarka, Olivier Valentin et al.
1 citation
preprint
Abstract Psilocybin, a psychoactive substance derived from fungi, has been utilized historically by diverse cultures for both medicinal and non-medicinal purposes, owing to its ability to elicit profound sensory and cognitive alterations and sustain long-term changes in mood and cognition. Promising results from recent clinical studies have generated a wave of interest in employing psilocybin...
Translational Psychiatry
September 30, 2024
Elizabeth L. Fisher, Ryan Smith, Kyna Conn et al.
14 citations
Psilocybin has shown promise as a novel pharmacological intervention for treatment of depression, where post-acute effects of psilocybin treatment have been associated with increased positive mood and decreased pessimism. Although psilocybin is proving to be effective in clinical trials for treatment of psychiatric disorders, the information processing mechanisms affected by psilocybin are not...
Middle East Research Journal of Biological Sciences
September 28, 2024
Carlos Henrique Marchiori, Marco Vinícios de Oliveira Santana, Klebert de Paula Malheiros
Psilocybin and psilocin do not cause addiction or dependence, as they do not interact with the dopaminergic reward system. New pharmacological treatment strategies for substance abuse disorders have targeted craving, which is characterized, in a simplified way, by an intense desire to use the substance. Psilocybin is an indole alkaloid of the hallucinogenic tryptamine group whose molecular...
Philosophical Psychology
September 26, 2024
Aleš Oblak, Liam Korošec Hudnik, Anja Levačić et al.
1 citation
There are profound methodological challenges facing microdosing research. One way we can address some of these methodological issues is by understanding how psilocybin microdosing fits in the broader existential context of people’s lives. We recruited participants who underwent psilocybin microdosing on their own and consented to being monitored for harm mitigation purposes. We combined...
Research Square
September 26, 2024
Shona G. Allohverdi, Milad Soltanzadeh, André Schmidt et al.
preprint
Abstract Ketamine and psilocybin show potential as therapies for various mental illnesses, including major depressive disorder. However, further investigation into their neural mechanisms is required to understand their effects on the brain. By combining computational modelling with electroencephalography (EEG), we examine the effects of ketamine and psilocybin on hierarchical sensory...
Psychedelics
September 24, 2024
Xi Zhu, Chen Zhang, David J Hellerstein et al.
6 citations
Body dysmorphic disorder (BDD) is a severe psychiatric condition characterized by preoccupation with perceived flaws in one's appearance, which the individual views as defective or ugly. Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, has emerged as a potential therapeutic agent for depression and other psychiatric disorders. This study aimed to identify subacute neural...
Frontiers in Psychiatry
September 23, 2024
Zhan-Ming Shi, Yu-Ping Ning, Xin-Hu Yang et al.
21 citations
Objectives The purpose of this systematic review of randomized controlled trials (RCTs) was to evaluate the effectiveness, safety, and tolerability of psilocybin in adult patients with major depressive disorder (MDD). Methods A systematic search (up to September 14, 2023) was conducted for RCTs that examined the efficacy, safety, and tolerability of psilocybin in physically healthy adult...